Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 14/20 | 0.62 |
| ▸ | ITGA2B | P08514 | 14/20 | 0.62 |
| ▸ | ITGAV | P06756 | 1/20 | 0.55 |
| ▸ | PPARG | P37231 | 2/20 | 0.51 |
| ▸ | MME | P08473 | 1/20 | 0.48 |
| ▸ | ACE | P12821 | 1/20 | 0.48 |
| ▸ | CPA1 | P15085 | 1/20 | 0.48 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.48 |
| ▸ | CTSL | P07711 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8775513 | 0.84 | ITGB3 (0.74) | ITGB3ITGA2BITGAVPPARGMME | |
| SCHEMBL8366722 | 0.84 | ITGB3 (0.71) | ITGB3ITGA2BITGAVPPARGMME | |
| SCHEMBL14485361 | 0.84 | ITGB3 (0.71) | ITGB3ITGA2BITGAVPPARGMME | |
| SCHEMBL5400258 | 0.82 | ITGB3 (0.79) | ITGB3ITGA2BITGAVPPARGHDAC8 | |
| SCHEMBL5400248 | 0.82 | ITGB3 (0.79) | ITGB3ITGA2BITGAVPPARGHDAC8 | |
| SCHEMBL10349352 | 0.82 | ITGB3 (0.78) | ITGB3ITGA2BITGAVCTSL | |
| SCHEMBL4894038 | 0.82 | LMNA (0.42) | ITGB3ITGA2BITGAVPPARG | |
| SCHEMBL5401333 | 0.81 | ITGB3 (0.76) | ITGB3ITGA2BITGAVPPARGHDAC8 | |
| SCHEMBL5401328 | 0.81 | ITGB3 (0.76) | ITGB3ITGA2BITGAVPPARGHDAC8 | |
| SCHEMBL4830419 | 0.81 | ITGB3 (0.70) | ITGB3ITGA2BITGAVPPARGMME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080021055-A1 | Novel cycloalkyl derivatives as inhibitors of bone resorption and vitronectin receptor antagonists | AVENTIS PHARMA S.A. | 2008-01-24 | — | — | US | disclosed |
| US-6399620-B1 | (2S)-2-(1-ADAMANTYL-METHYLOXYCARBONYLAMINO)-3-(4-(3-GUANIDINO -CARBONYL-PROPYLOXY)PHENYL)PROPIONIC ACID; ANTITUMOR AGENTS; ANTIINFLAMMATORY AGENTS; CARDIOVASCULAR DISORDERS | AVENTIS PHARMA S.A. (DE) | 2002-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021055-A1 | Novel cycloalkyl derivatives as inhibitors of bone resorption and vitronectin receptor antagonists | ADGRF1, ADGRE5, CALCR | ITGB3 536/4885ITGA2B 379/4885ITGAV 737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.